Home > Healthcare > Biotechnology > Biotechnology R&D > Induced Pluripotent Stem Cells Production Market

Induced Pluripotent Stem Cells Production Market Size

Report ID: GMI7651
Published Date: Dec 2023
Report Format: PDF

Download Free Sample

Induced Pluripotent Stem Cells Production Market Size

Induced Pluripotent Stem Cells Production Market size was valued USD 1.4 billion in 2023 and is estimated to expand at 9.8% CAGR from 2024 to 2032. The expanding field of drug discovery and development has fuelled the demand for iPSCs, as they provide a valuable platform for modelling diseases and testing potential treatments.

To get key market trends

Download Free Sample

Also, the vast therapeutic potential of stem cell-based therapies, growing incidence of cancer/oncology, increasing capital investments for stem cell-based research, and multiple advantages of induced pluripotent stem cells (iPSCs) over embryonic stem cells (ESCs) are driving the market growth. For instance, according to the American Cancer Society, in 2023, it is anticipated that, approximately 1.9 million fresh cases of cancer will be diagnosed and around 609,820 deaths due to cancer in the U.S. Therefore, collaborative efforts between academic institutions, research organizations, and pharmaceutical companies will contribute to the expansion of iPSC therapeutic capabilities for such diseases, thereby fostering the market progress.

Induced pluripotent stem cells (iPSCs) production refers to the process of reprogramming differentiated cells into a pluripotent state. Pluripotent stem cells are cells that can differentiate into various cell types found in the human body. iPSCs are particularly significant because they share similar characteristics with embryonic stem cells, but they are derived without the need for the destruction of embryos.

Induced Pluripotent Stem Cells Production Market Report Attributes
Report Attribute	Details
Base Year:	2023
Induced Pluripotent Stem Cells Production Market Size in 2023:	USD 1.4 Billion
Forecast Period:	2024 to 2032
Forecast Period 2024 to 2032 CAGR:	9.8%
2032 Value Projection:	USD 3.4 Billion
Historical Data for:	2018 to 2023
No. of Pages:	220
Tables, Charts & Figures:	311
Segments covered:	Process, Product & Service, Application, End-use, & Region
Growth Drivers:	Rising incidence of cancer Significant therapeutic potential of iPSC Increased applications in drug discovery & development
Pitfalls & Challenges:	Stringent regulatory requirements High production cost

Learn more about the key segments shaping this market

Download Free Sample

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Induced pluripotent stem cells production industry size was worth USD 1.4 billion in 2023 and is anticipated to reach USD 3.4 billion by 2032 driven by the expanding field of drug discovery and development.

The consumables & kits segment held a sizable revenue share in 2022 and is expected to depict an 8.9% growth rate from 2024 to 2032 propelled by the escalating adoption of iPSC technology across various scientific disciplines, including regenerative medicine and drug discovery.

North America induced pluripotent stem cells production market accounted for 41.3% of revenue share in 2022 and is poised to exhibit notable growth through 2032 attributed to a robust infrastructure for biotechnology R&D, coupled with significant investments in healthcare and life sciences.

The leading companies engaged in the induced pluripotent stem cells production industry are Lonza, Axol Biosciences Ltd., Evotec SE, Hitachi Ltd., Merck KGaA, Thermo Fisher Scientific, Inc., Applied StemCells, Inc., Creative Biolabs, and Bio-Techne Corporation, among others.